VEA
MYGN icon

Virtus ETF Advisers’s Myriad Genetics MYGN Stock Holding History

Virtus ETF Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Buy
20,502
+502
+3% +$2.28K 0.04% 352
2026
Q1 		$90K Hold
20,000
– – 0.04% 343
2025
Q4 		$123K Buy
+20,000
New +$145K 0.06% 312

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtus ETF Advisers's MYGN Position: Q2 2026 in Review

Virtus ETF Advisers increased its Myriad Genetics (MYGN) stake by 2.5% in Q2 2026, buying an estimated $2.28K and bringing the position to 20,502 shares worth $117K. The position accounts for 0.04% of the portfolio, ranked #352.

Virtus ETF Advisers first reported a position in MYGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $123K in Q4 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Virtus ETF Advisers held 20,502 shares of Myriad Genetics worth $117K as of Q2 2026.
  • Virtus ETF Advisers bought 502 Myriad Genetics shares in Q2 2026, an estimated $2.28K.
  • Myriad Genetics made up 0.04% of Virtus ETF Advisers's portfolio in Q2 2026, its #352 holding.
  • Virtus ETF Advisers first reported a position in Myriad Genetics in Q4 2025 and has held it in 3 quarters since.
  • Virtus ETF Advisers's Myriad Genetics position peaked at $123K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.